◂ Announcements

Sep 18, 2020ACQUISITIONUnited States

QIAGEN completes buyout of NeuMoDx for $248 million

QIAGEN N.V. completed the acquisition of the remaining 80.1% stake in NeuMoDx Molecular, Inc. for $248 million in cash, gaining full ownership of the diagnostics instruments company.

Value

$248.0M

Status

Completed

Productsautomated molecular testing platformsPCR-based diagnostic assays

CompaniesQiagen acquirer NeuMoDx Molecular target

Sectors#Medical Devices

“The buyout of NeuMoDx completes QIAGEN's portfolio of automated molecular testing solutions based on the polymerase chain reaction technology.”nasdaq.com

1 source
nasdaq.comQIAGEN (QGEN) Completes Buyout of NeuMoDx, Expands PortfolioSep 18, 2020

Summarized from public sources; check the original articles before acting on it.

More from Qiagen

profile ▸

Dec 11, 2020EXPANSIONGermantown, Maryland, United States$7.00M80 jobs
QIAGEN expands Germantown, Maryland manufacturing facility for COVID-19 testing
Qiagen business.maryland.gov
Mar 3, 2020ACQUISITION$11.5B
Thermo Fisher Scientific to acquire Qiagen for $11.5 billion
Thermo Fisher Scientific acquirer Qiagen target clpmag.com
Sep 17, 2018PARTNERSHIP$234.0M
Qiagen partners with NeuMoDx on PCR systems with option to acquire for $234M
Qiagen NeuMoDx Molecular partner insideprecisionmedicine.com

Loading…

QIAGEN completes buyout of NeuMoDx for $248 million · Endata